A new Cambridge biotech is creating a roadmap to expand preventive health to a broader range of diseases, treating patients ...

Pittsburgh biotech firms see potential benefits from upcoming tariffs and reshoring efforts, despite uncertainties in NIH ...

STAT's Adam Feuerstein puts all his “Biotech Doom Loop” panic-mongering aside, as he embraces luminescent moonbeams and downy ...

Tariff worries continue hanging over companies as they report their latest financial results and try to provide guidance on ...

Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing ...

CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, ...

The full abstract will be available on the ASCO® website on May 22, 2025, at 5:00 p.m. ET.

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Dr. Rietiker has considerable experience in the life sciences industry, including leadership positions in global pharmaceutical and medical device companies, and has overseen multiple major company ...

The Trump administration’s threat of pharmaceutical tariffs could risk significant political backlash, as the drug industry ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any anti-diabetic medication and have been managing their condition through diet and ...